Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT003 Hemodynamics in COPD
NCT02685293Phase 3Terminated
- Sponsor
- Pearl Therapeutics
- Start
- Dec 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of glycopyrrolate metered dose inhaler, formoterol fumarate in chronic obstructive pulmonary disease (COPD), sponsored by Pearl Therapeutics. Started Dec 2016; status: terminated.
02
Drugs
glycopyrrolate metered dose inhalerformoterol fumarate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02685293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02685293.